MediciNova asthma drug fails trial; shares crash
MediciNova asthma drug fails trial; shares crashReutersMediciNova, which is testing MN-221 as a treatment for acute asthma attacks not responsive to standard therapy, said the drug failed to show a statistically significant improvement over a placebo. MN-221 looks to treat the condition by bypassing ...MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma ...MarketWatch (press release)MediciNova Misses Primary Goal in Mid-Stage Trial of IV Asthma DrugXconomyMediciNova shares crash after lead asthma drug fails IIb trialFierceBiotechall 26 news articles »
New Phase 3 data for Tradjenta® (linagliptin) tablets in black or African ...
New Phase 3 data for Tradjenta® (linagliptin) tablets in black or African ...MarketWatch (press release)[4] In the 24-week study, 226 patients were randomized (106 to linagliptin, and 120 to placebo)[1], and received at least one dose of the study drug in order to be included in the safety analyses.[1] Patients who had a measurement of A1C at baseline ...Lilly Optimistic on Type-2 Diabetes Drug for Black PatientsFox BusinessLilly, BI diabetes drug shows greater A1C reduction in African-American adults ...Drug Store NewsTradjenta Proves Effective in African Americans with Type 2 DiabetesA Sweet LifeRTT Newsall 10 news articles »
Aspirin Found To Prevent Recurrent Venous Thromboembolism
Aspirin Found To Prevent Recurrent Venous ThromboembolismForbesFollowing 6 to 18 months of oral anticoagulation, 403 patients with first-time unprovoked VTE were randomized to aspirin (100 mg daily) or placebo for two years. Aspirin therapy resulted in a significant reduction in VTE but did not cause an increase ...Aspirin May Reduce Risk of Repeat Blood ClotsWebMDAspirin Cuts Recurrent VTE After Stopping WarfarinMedPage TodayAspirin May Prevent Recurrence of Deep Vein Blood ClotsU.S. News & World ReportDoctors Loungeall 11 news articles »
Shire Presents Data on Venvanse
Shire Presents Data on VenvanseZacks.comIn this phase III double-blind, placebo-controlled, randomized study, long-term maintenance of efficacy and safety of Venvanse in children and adolescents aged 6 to 17 years with moderately symptomatic ADHD was evaluated. Significantly less treatment ...Efficacy of Shire's Vyvanse maintained in ADHD adolescents after at least six ...The Pharma Letterall 4 news articles »
Lilly's GLP-1 Agonist Delivers
Lilly's GLP-1 Agonist DeliversZacks.comResults from the phase II, randomized, double-blind, placebo-controlled, 26-week, parallel study showed that dulaglutide achieved non-inferiority after 16 weeks for mean 24-hour systolic blood pressure (SBP). Two doses (0.75 mg and 1.5 mg) of ...Lilly Diabetes Presents Phase II Blood Pressure…Pharmaceutical ProcessingDulaglutide passes BP hurdle, but heart-rate increase observedTheHeart.OrgEli Lilly's diabetes drug meets mid-stage trial goalReutersFox Businessall 33 news articles »
Placebo Tickets and Information - We offer a variety tickets for Placebo and all Placebo events. We Guarantee all Placebo tickets to be 100% Authentic and offer a money back Guarantee . We have access to Front Row Tickets for Placebo, VIP Placebo Tickets , VIP Placebo Packages, Meet and Greet, Special Access Tickets, and we even have Placebo Parking Passes. Find Placebo Dates, Placebo Times, Placebo schedules, Placebo information, and Placebo Tickets.